ATE260106T1 - Verbindungen mit antihypertensiven, cardioprotektiven, anti-ischämischen und antilipolytischen eigenschaften - Google Patents

Verbindungen mit antihypertensiven, cardioprotektiven, anti-ischämischen und antilipolytischen eigenschaften

Info

Publication number
ATE260106T1
ATE260106T1 AT95916451T AT95916451T ATE260106T1 AT E260106 T1 ATE260106 T1 AT E260106T1 AT 95916451 T AT95916451 T AT 95916451T AT 95916451 T AT95916451 T AT 95916451T AT E260106 T1 ATE260106 T1 AT E260106T1
Authority
AT
Austria
Prior art keywords
cardioprotective
antihypertensive
ischemic
compounds
antilipolytic
Prior art date
Application number
AT95916451T
Other languages
English (en)
Inventor
Alfred P Spada
Cynthia A Fink
Michael R Myers
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Application granted granted Critical
Publication of ATE260106T1 publication Critical patent/ATE260106T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95916451T 1994-04-19 1995-04-19 Verbindungen mit antihypertensiven, cardioprotektiven, anti-ischämischen und antilipolytischen eigenschaften ATE260106T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22988294A 1994-04-19 1994-04-19
US08/316,761 US5561134A (en) 1990-09-25 1994-10-03 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
PCT/US1995/004800 WO1995028160A1 (en) 1994-04-19 1995-04-19 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties

Publications (1)

Publication Number Publication Date
ATE260106T1 true ATE260106T1 (de) 2004-03-15

Family

ID=26923699

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95916451T ATE260106T1 (de) 1994-04-19 1995-04-19 Verbindungen mit antihypertensiven, cardioprotektiven, anti-ischämischen und antilipolytischen eigenschaften

Country Status (28)

Country Link
US (2) US5561134A (de)
EP (2) EP0758897B1 (de)
JP (1) JPH09512020A (de)
KR (1) KR970702045A (de)
CN (1) CN1086704C (de)
AP (1) AP699A (de)
AT (1) ATE260106T1 (de)
AU (1) AU684635B2 (de)
BG (1) BG63799B1 (de)
BR (1) BR9507327A (de)
CA (1) CA2188147C (de)
CZ (1) CZ289528B6 (de)
DE (1) DE69532608T2 (de)
DK (1) DK0758897T3 (de)
EE (1) EE9600156A (de)
ES (1) ES2217279T3 (de)
FI (1) FI964218A7 (de)
HU (1) HUT75331A (de)
NO (1) NO317727B1 (de)
NZ (1) NZ284357A (de)
OA (1) OA10464A (de)
PL (1) PL182942B1 (de)
PT (1) PT758897E (de)
RO (1) RO119225B1 (de)
RU (1) RU2166319C2 (de)
SI (1) SI9520055A (de)
SK (1) SK284039B6 (de)
WO (1) WO1995028160A1 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US5792776A (en) * 1994-06-27 1998-08-11 Cytomed, Inc., Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
CZ286483B6 (en) * 1995-05-30 2000-04-12 Rhone Poulenc Rorer Sa Derivatives of 2-azabicyclo/2,2,1/heptane and process of their preparation
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
US6376472B1 (en) 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5747474A (en) * 1996-07-29 1998-05-05 Immune Modulation, Inc. Immunosuppression by administration of N6,N6 -disubstituted cAMP's, analogues thereof, and related nucleosides
AU4377397A (en) * 1996-10-14 1998-05-11 Novo Nordisk A/S Novel therapeutically active adenosine derivatives
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
EA003645B1 (ru) * 1998-12-21 2003-08-28 Авентис Фармасьютикалз Инк. Способ получения n6-замещенных производных деаза-аденозина
CN1383427A (zh) 1998-12-31 2002-12-04 阿温蒂斯药物公司 制备n6－取代的脱氮杂一腺苷衍生物的方法
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7018365B2 (en) 1999-05-21 2006-03-28 Micro Therapeutics, Inc. Threaded syringe with quick stop
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
DE19951701A1 (de) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Verwendung von 2-Imidazolyl-substituierten Carbinolen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
US6368573B1 (en) * 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US20020045613A1 (en) * 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
AU2002362443B2 (en) * 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
US7086397B2 (en) * 2002-02-16 2006-08-08 Graham Lindley Spruiell Patient usable emergency medical kit
WO2003070739A1 (en) * 2002-02-19 2003-08-28 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
ATE486608T1 (de) * 2002-03-26 2010-11-15 Forbes Medi Tech Inc Medizinische verwendung von anthocyaninen aus schwarzreis
WO2003086408A1 (en) * 2002-04-10 2003-10-23 University Of Virginia Patent Foundation Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
US7265111B2 (en) * 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
WO2005058228A2 (en) * 2003-12-19 2005-06-30 F. Hoffmann-La Roche Ag Comt inhibitors
EP1574508A1 (de) 2004-01-30 2005-09-14 Lonza AG Verfahren zur Herstellung von Acetalen und Ketalen von 3-Amino-5-(hydroxymethyl)-cyclopentan-1,2-diolen, sowie deren Derivaten und Salzen
WO2005097766A1 (en) * 2004-03-31 2005-10-20 Lexicon Genetics, Inc. 2-aminomethylthiazole-5-carboxamides as protein kinase modulators
US7442687B2 (en) * 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
NZ585697A (en) * 2004-08-02 2011-12-22 Univ Virginia Patent Found 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
AU2006285005B2 (en) * 2005-08-30 2012-03-29 Abbvie Inc. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20080027022A1 (en) * 2006-02-08 2008-01-31 Linden Joel M Method to treat gastric lesions
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
KR20150038395A (ko) 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
US20110160232A1 (en) * 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
RU2363453C1 (ru) * 2008-03-25 2009-08-10 Олег Николаевич Моисеев Способ лечения трихомоноза крупного рогатого скота
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
AR075899A1 (es) * 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
CA2789950C (en) 2010-02-18 2018-09-04 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3238722B1 (de) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Festen formen von isochinolinonen
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (de) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und ihre verwendung
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (de) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und verwendungen davon
US10301348B2 (en) * 2013-10-23 2019-05-28 Academia Sinica Compounds for use in prevention and treatment of neurodegenerative diseases and pain
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (de) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Kombinationstherapie

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL128629C (de) * 1966-05-07
DE2524284A1 (de) * 1966-12-21 1976-10-28 Boehringer Mannheim Gmbh Adenosin-derivate und verfahren zu ihrer herstellung
BE768925A (fr) * 1970-06-30 1971-11-03 Takeda Chemical Industries Ltd Derives d'adenosine et procede de preparation
DE2059922A1 (de) * 1970-12-05 1972-06-15 Boehringer Mannheim Gmbh Neue N(6)-Aralkyl-adenosin-Derivate und Verfahren zur Herstellung derselben
DE2205002A1 (de) * 1972-02-03 1973-08-09 Merck Patent Gmbh Adenosinderivate
DE2136624A1 (de) * 1971-07-22 1973-02-08 Boehringer Mannheim Gmbh N (6)-substituierte adenosin-derivate und verfahren zur herstellung derselben
DE2139107A1 (de) * 1971-08-04 1973-02-15 Merck Patent Gmbh Heterocyclisch substituierte adenosinverbindungen
DE2151013C2 (de) * 1971-10-08 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von in N↑6↑-Stellung gegebenenfalls substituierten 6-Amino- und 2,6-Diaminopurinnucleosiden
US3864483A (en) * 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
US3931401A (en) * 1972-10-21 1976-01-06 Abbott Laboratories 1,N6 -etheno-5'-adenosine carboxamides for increasing coronary sinus partial pressure of oxygen
US3914415A (en) * 1973-06-14 1975-10-21 Abbott Lab Adenosine-5{40 -carboxylic acid amides
US4167565A (en) * 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4340730A (en) * 1980-06-09 1982-07-20 G. D. Searle & Co. N6 -Substituted adenosines
JPS59219284A (ja) * 1983-05-27 1984-12-10 Toyo Jozo Co Ltd ３′−デオキシネプラノシンａおよびその製造法
CA1239397A (en) * 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
US4501735A (en) * 1983-12-05 1985-02-26 Warner-Lambert Company N6-(1- and 2-benzocycloalkyl) adenosines
EP0300145A3 (de) * 1984-04-18 1989-08-30 Whitby Research Incorporated N-6-substituierte Phenyladenosinderivate als herzwirksame Vasodilatoren
US4657898A (en) * 1984-06-22 1987-04-14 Warner-Lambert Company N6 -substituted adenosines and method of use
US4657897A (en) * 1984-06-22 1987-04-14 Warner-Lambert Company N6 -substituted adenosines for treating pain
US5310731A (en) * 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US4582823A (en) * 1984-08-15 1986-04-15 Warner-Lambert Company Method for treating schizophrenia and medicaments therefor
AU575438B2 (en) * 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4683223A (en) * 1985-09-09 1987-07-28 Warner-Lambert Company N6 -Benzopyrano-and benzothiopyrano adenosines and methods of use
US4663313A (en) * 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4593019A (en) * 1984-10-26 1986-06-03 Warner-Lambert Company N6 -tricyclic adenosines
US4636493A (en) * 1985-01-25 1987-01-13 Warner-Lambert Company Benzothien-3-yl adenosine; benzothien-3-yl adenosine, S-oxide; and benzothien-3-yl, S,S-dioxide adenosine compounds
US4600707A (en) * 1985-01-25 1986-07-15 Warner-Lambert Company Benzothien-3-yl adenosine; benzothien-3-yl adenosine, S-oxide; and benzothien-3-yl, S,S-dioxide adenosine compounds
DE3529497A1 (de) * 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4755594A (en) * 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
WO1988003148A2 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
AU8276187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
IL84414A0 (en) * 1986-11-14 1988-04-29 Ciba Geigy Ag N9-cyclopentyl-substituted adenine derivatives
US5063233A (en) * 1986-11-14 1991-11-05 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives useful as adenosine receptor agonists
US4843066A (en) * 1986-11-27 1989-06-27 Nippon Zoki Pharmaceutical Co., Ltd. Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient
NL8702926A (nl) * 1986-12-15 1988-07-01 Sandoz Ag Nieuwe furanuronzuurderivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
PT86660B (pt) * 1987-02-04 1992-02-28 Ciba Geigy Ag Processo para a preparacao de derivados de adenosina-5'-carboxamida
CA1340361C (en) * 1987-04-24 1999-02-02 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
AU3820989A (en) * 1988-08-02 1990-02-08 Ciba-Geigy Ag 7-amino-3-beta-d-ribofuranosyl-3h-imidazo(4,5-b) pyridin-5-amine derivatives
US4977144A (en) * 1988-08-02 1990-12-11 Ciba-Geigy Corporation Imidazo[4,5-b]pyridine derivatives as cardiovascular agents
GB2226027B (en) * 1988-12-13 1992-05-20 Sandoz Ltd Adenosine derivatives,their production and use
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
GB8916480D0 (en) * 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
ES2095960T3 (es) * 1990-09-25 1997-03-01 Rhone Poulenc Rorer Int Compuestos que tienen propiedades antihipertensivas y antiisquemicas.
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate

Also Published As

Publication number Publication date
MX9604999A (es) 1998-05-31
AP9600904A0 (en) 1997-01-31
BG100963A (en) 1997-08-29
DE69532608D1 (de) 2004-04-01
OA10464A (en) 2002-04-03
KR970702045A (ko) 1997-05-13
PL316961A1 (en) 1997-02-17
SK134096A3 (en) 1997-05-07
WO1995028160A1 (en) 1995-10-26
NO964438D0 (no) 1996-10-18
BR9507327A (pt) 1997-10-07
NO964438L (no) 1996-10-18
HU9602829D0 (en) 1996-12-30
RO119225B1 (ro) 2004-06-30
CN1086704C (zh) 2002-06-26
EP1006115A3 (de) 2000-06-28
FI964218A0 (fi) 1996-10-18
EP0758897B1 (de) 2004-02-25
DE69532608T2 (de) 2005-01-05
US5561134A (en) 1996-10-01
BG63799B1 (bg) 2003-01-31
SK284039B6 (sk) 2004-08-03
CZ289528B6 (cs) 2002-02-13
HK1011294A1 (en) 1999-07-09
FI964218L (fi) 1996-12-17
AP699A (en) 1998-12-01
DK0758897T3 (da) 2004-05-03
CA2188147C (en) 2001-04-03
JPH09512020A (ja) 1997-12-02
EP1006115A2 (de) 2000-06-07
CA2188147A1 (en) 1995-10-26
SI9520055A (en) 1997-06-30
AU684635B2 (en) 1997-12-18
FI964218A7 (fi) 1996-12-17
HUT75331A (en) 1997-05-28
PL182942B1 (pl) 2002-05-31
AU2294995A (en) 1995-11-10
US5736554A (en) 1998-04-07
PT758897E (pt) 2004-07-30
EP0758897A1 (de) 1997-02-26
CN1148811A (zh) 1997-04-30
CZ303296A3 (en) 1997-05-14
NZ284357A (en) 2001-06-29
ES2217279T3 (es) 2004-11-01
EP0758897A4 (de) 1997-11-19
RU2166319C2 (ru) 2001-05-10
EE9600156A (et) 1997-06-16
NO317727B1 (no) 2004-12-13

Similar Documents

Publication Publication Date Title
ATE239725T1 (de) Verbindungen mit antihypertensiven, cardioprotektiven, antiischämischen und antilipolytischen eigenschaften
DE69532608D1 (de) Verbindungen mit antihypertensiven, cardioprotektiven, anti-ischämischen und antilipolytischen eigenschaften
FI933885L (fi) Kaerl av plast, isynnerhet groensakskaerl, med vikbara sidovaeggar
DE69736711D1 (de) Substituierte 6,5-heterobicyclische-derivate
DK0925298T3 (da) Substituerede 6,6-heterobicykliske derivater
DE59711118D1 (de) Spickeln, Zunehmen und Mindern
DE69416634D1 (de) Anorganische, abbindende Zusammensetzung
DE59709806D1 (de) Cycloolefincopolymere, ihre verwendung und daraus hergestellte formkörper
DE69332949D1 (de) Feste, stäbchenförmige polymere
ATE231847T1 (de) Substituierte 1,2,3,4- tetrahydronaphthalinderivate
EE200100347A (et) 3,3-biarüülpiperidiini ja 2,2-biarüülmorfoliini derivaadid
DK0688196T3 (da) Med åbninger forsynede implantatsystemer
DE69714358D1 (de) 9,10-disubstituierte campothecinderivate mit antitumoraktivität
PT1129079E (pt) Derivados de triazina 2,4-dissubstituidos
DE59703521D1 (de) Gemische mit 1,1,1,3,3-pentafluorbutan
BR9708948A (pt) 1,3 - Benzodioxois substituídos
BR9701404A (pt) Derivados de 1,25-diidróxi-16,22,23-trisdeidro-colecal-ciferol
HK1019876A (en) Compounds having antihypertensive cardioprotective, anti-ischemic and antilipolytic properties
DK0641754T3 (da) Kompostsilo, der består af flere dele
FI964381A0 (fi) Foerfarande foer rengoering av nedsmutsat material, saosom jordmaterial
FI1336U1 (fi) Vaermevaexlare foer uppvaermning av uteluft med vatten, skaerkilt i s.k. vertikalvindkraftverk
FI1391U1 (fi) Utrymme, saosom bastu av elementkonstruktion
KR960030126U (ko) 바이오 세라믹이 내장된 넥타이
FI955239A0 (fi) Foerfarande foer behandling av kornigt, med tungmetaller foerorenat material
FI962118A0 (fi) Foerbaettrad anordning foer behandling av roekgaser, saerskilt avgaser

Legal Events

Date Code Title Description
EEFA Change of the company name
UEP Publication of translation of european patent specification

Ref document number: 0758897

Country of ref document: EP